Arin战术极端风险主动型ETF ATTR 深 沪
已收盘 11-06 16:00:00 美东时间
95.80
-0.130
-0.14%
华盛通- 最 高95.87
- 今 开95.87
- 成交量 380股
- 最 低 95.80
- 昨 收 95.93
- 总市值 9475.58万
- 52周最高 96.76
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 88.71
- 委 比 0.00%
- 总股本 98.91万
- 历史最高 96.76
- 量 比 0.04
- 振 幅 0.07%
- 历史最低 88.71
- 每 手 1
- 风险率 2.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
Intellia Therapeutics will present new clinical data on nex-z, a CRISPR-based treatment for transthyretin amyloidosis, at two medical meetings in November. At the American Heart Association (AHA) Scientific Sessions 2026, cardiac outcomes from a single dose of nex-z in patients with mixed phenotype ATTRv-PN will be highlighted. At the International Society of Amyloidosis (ISA) 2026 Symposium, long-term follow-up data from the Phase 1 trial in ATT...
11-03 13:00
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
BridgeBio Pharma will present five posters and one Abbott-supported poster on acoramidis and ATTR-CM at the American Heart Association Scientific Sessions 2026. The data highlight acoramidis as a first-line treatment for ATTR-CM, being the only selective, oral, near-complete TTR stabilizer. Acoramidis is approved as Attruby® in the U.S. and BEYONTTRA® in Europe and other regions. The posters cover diagnosis, AI screening, and clinical outcomes, e...
11-03 12:30
阿尔尼拉姆2026年第三季度财报：AMVUTTRA推动产品收入增长52%
阿尔尼拉姆制药（Alnylam Pharmaceuticals）2026年第三季度营收同比增长17%至14.58亿美元；受AMVUTTRA销售额攀升65%至11.30亿美元推动，产品净收入增长52%至12.92亿美元。GAAP稀释后每股收益达到15.72美元，而上年同期为2.14美元，这主要反映了19亿美元的所得税收益，而非经营性增长。由于产品成本、研发及商业化支出增加，GAAP营业利润下降6%至3.458亿美元。阿尔尼拉姆重申了2026年全年业绩指引，包括47亿至51亿美元的产品净收入。
10-29 12:14
Alnylam Q3 2026 Earnings: AMVUTTRA Drives 52% Product Revenue Growth
Alnylam Pharmaceuticals’ Q3 2026 revenue rose 17% to $1.458 billion, while net product revenue increased 52% to $1.292 billion as AMVUTTRA sales climbed 65% to $1.130 billion. Diluted GAAP EPS reached $15.72 versus $2.14 a year earlier, largely reflecting a $1.9 billion income tax benefit rather than operating growth. GAAP operating income fell 6% to $345.8 million as product costs, R&D, and commercial spending increased. Alnylam reiterated full-
10-29 12:13
AstraZeneca PLC Stock (AZN) Moved Up by 3.04% on Oct 22: A Full Analysis
• FDA granted accelerated approval for Ultomiris to treat primary IgA nephropathy. • AstraZeneca reports annual revenue of $58.74B and net profit of $10.22B. • Analysts issued Buy ratings with an average price target of $210.32.
10-22 18:15
AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis
• AstraZeneca partnered with Summit Therapeutics for next-generation oncology collaborations and antibody development. • Analysts raised full-year earnings per share projections ahead of quarterly financial reports. • Annual revenue reached $58.74 billion with net profit at $10.22 billion.
10-14 15:15
Bayer’s experimental PET tracer shows accuracy in Phase 3 cardiac amyloidosis
Bayer (BAYZF) said an experimental imaging agent accurately identified cardiac amyloidosis in a Phase 3 study, producing sensitivity of 94% and specificity of 86% based on agreement among independent ...
08-31 06:23
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case
Alnylam Pharmaceuticals (ALNY) on Sunday presented new analyses supporting the use of Amvuttra across a range of patients with transthyretin amyloidosis, including those already receiving Pfizer’s taf...
08-31 00:43
Alnylam initiated an outperform at BMO on RNAi pipeline
BMO Capital Markets initiated Alnylam Pharmaceuticals (ALNY) with an outperform rating, citing its RNAi pipeline and growth in its ATTR franchise. The firm has a price target of $318 (~39% upside base...
08-20 00:02
Intellia upgraded at Evercore ISI on nex-z hypothesis
Shares of Intellia Therapeutics (NTLA) traded higher in the premarket on Friday after Evercore ISI upgraded the gene-editing biotech to Outperform from Inline, citing the company’s latest findings on ...
08-07 20:30
